Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

78 J a n u a r y / F e b r u a r y 20 0 2 PharmaVOICE to Dr. Lars Ekman, president of bio pharmaceutical R&D. Dr. Pilgrim received her M.D. and Ph.D. from Oxford University. Robert P. LUCIANO LongServing Executive Retires from ScheringPlough Board Chairman emeri tus and a director of ScheringPlough Corp., Robert P. Luciano, has retired from the board of d i r e c t o r s . M r. Luciano had been w i t h S c h e r i ng Plough for 23 years and previously served as chairman of the board from 1984 to 1998 and as CEO from 1982 to 1996. “Bob Luciano and I have worked closely together over many years at ScheringPlough,” says Richard Jay Kogan, chairman and CEO of the Kenil worth, N.J.based company. “I know firsthand his great contribution to this company and his role in bringing us to where we are today, a leader in our indus try. His personal help to me over the years would be hard to overstate. “Since he has decided to step down now as a member of our board of directors, I have no choice but to accept and respect his wish,” Mr. Kogan says. “I am very grateful that Mr. Luciano will continue to be available to me as a continuing source of guidance and wisdom. On behalf of my colleagues on the board, I thank him for his service and will continue to value his coun sel and friendship.” Charles PORTWOOD AHPAppoints President of Global Supply Chain For WyethAyerst Pharmaceuticals American Home Products Corp. has appointed Charles Portwood as president of the global supply chain for WyethAyerst Pharmaceuticals — the company’s phar maceutical division. Mr. Portwood is based in Wyeth Ayerst’s Radnor, Pa., offices, is succeed ing Jack Bucceri who has decided to retire at the end of this year. Mr. Bucceri headed WyethAyerst’s supply chain organization for more than nine years and steered the company through a broad range of key milestones and


Pharma POOL

Michael GEORGE
Alison PILGRIM,M.D.,Ph.D
Elan Appoints Senior Management

Completing a yearlong program to enhance and expand the Elan Corp.’s biopharmaceutical senior executive team, Chairman and CEO Donal J. Geaney named two industry professionals — Alison Pilgrim, M.D., Ph.D, as senior VP of clinical development and Michael George as president, North America. Mr. George has more than 28 years of expe rience in the lifesciences and healthcare fields, most recently as CEO of UroCor Inc., before its acquisition on Nov. 9, 2001, by Dianon Systems Inc. During his twoyear tenure there as CEO the company’s revenue increased by 50% and its marketcapitalization quadru pled. Mr. George’s primary focus at Dublin, Irelandbased Elan is on consolidating and strengthening the company’s recently inte grated U.S. businesses. He reports directly to Daniel Welch, president of worldwide bio pharmaceuticals. Dr. Pilgrim, who joins the biopharmaceu ticals division, has extensive international experience in the clinical development of neu rology, metabolic, antiinflammatory, cardio vascular, and HIV compounds. She has held senior clinical positions at Glaxo Wellcome, SanofiSynthelabo, and most recently as head of clinical development for DuPont Pharma ceuticals. During her 16 years in the industry, Dr. Pilgrim made significant contributions in the clinical development of several block buster products, including a leadership role in the development of Glaxo Wellcome’s Suma triptan and Sanofi’s Plavix. Dr. Pilgrim reports EXECUTIVE APPOINTMENTS AND PROMOTIONS IN THE HEALTHCARE INDUSTRY IVAX FOUNDER NAMED 2001 NATIONAL ERNST &YOUNG ENTREPRENEUR OFTHEYEAR Phillip FROST,M.D. The 15th Annual Ernst & Young Entrepreneur Of The Year Awards has selected Phillip Frost, M.D., founder, chairman, and CEO of Ivax Corp. as the 2001 Entrepreneur Of The Year. Dr. Frost engineered the growth of Miami based Ivax into one of the world’s largest generic pharmaceutical companies. He is credited with keeping Ivax alive through a difficult period in 1996, when issues affecting the entire pharmaceu tical industry caused Ivax to lose a significant amount of its income. Today, the company has a rich pipeline of both generic and proprietary products in development, and has received a substantial order from the U.S. government for antibiotics that treat anthrax. Dr. Frost was selected for the 2001 National Ernst &Young Entrepreneur Of The Year award by an independent panel of judges from a pool of more than 5,600 nominees from around the country. He also took top honors in the Entrepreneur Of The Year Health Sciences award category. This year’s national award winners were acknowledged at an awards ceremony in Palm Springs, Calif., on Nov. 17, 2001. Dr. Frost, right, accepts the 2001 National Ernst & Young Entrepreneur of The Year Award. TALENT pool issues, including the integration of Lederle’s manufacturing operations, the development of an overall supply chain organizational strategy, and globalization of the WyethAyerst’s man ufacturing network. Mr. Portwood is responsible for all aspects of the global supply chain for WyethAyerst including pharmaceuticals, OTC products, and vaccines. He joins WyethAyerst from Aventis Pharmaceuticals, where he most recently was senior VP of strategy and indus trial excellence. Mr. Portwood earned a B.S. degree from Purdue University and a masters degree in business administration at Xavier University, Cincinnati, Ohio. StephanieSEREMETIS,M.D. Scott HOCKING Novo Nordisk Appoints New Medical Director, Announces Promotion Novo Nordisk Pharmaceuticals Inc. has appointed Stephanie Seremetis, M.D., as med ical director of its BioPharmaceuticals busi ness unit. Dr. Seremetis is responsible for all clinical research involving the company’s biopharma ceutical products and will lead all medical liaison and medical affairs activi ties within the division. Dr. Seremetis comes to Novo Nordisk, Prince ton, N.J., from the Mount Sinai School of Medicine in New York City, where she was an associate professor of both the Departments of Medicine and Geriatrics. Dr. Seremetis also was director of the Regional Comprehensive Hemophilia Diagnostic and Treatment Cen ter. Building on a longstanding interest and outstanding ability to motivate an interdisci plinary team, she was the founding director of the Women’s Health Program at Mount Sinai Medical Center. This center successfully coor dinated comprehensive clinical care, teaching, and research in women’s health. Dr. Seremetis has authored numerous publi cations in the areas of hematology and hemophilia and has been a reviewer for many medical journals, including The Journal of the American Medical Association and Lancet. In addi tion, she has served on many committees for organizations such as the National Hemophilia Foundation, the National Institutes of Health, and the World Health Organization. Dr. Seremetis received her medical degree from the School of Medicine of State Universi ty of New York in Stony Brook and her bach elor’s degree in biology from Cornell Univer sity. Separately, Novo Nordisk has promoted Scott Hocking to director, managed care, trade, and government, operations. He was account executive, managed care, in New England before his promotion. In his new position, Mr. Hocking is responsible for such areas as pharmacoeco nomics, pricing, accountspecific data moni toring, and training. Mr. Hocking joined NNPI in March 2000 as a regional account manager in the North east. He received a bachelor’s degree in public health from the University of Massachusetts and a juris doctorate degree from the New England School of Law. 80 J a n u a r y / F e b r u a r y 20 0 2 PharmaVOICE Biotech POOL Frank A. BURKE, Jr. GuyCharles FANNEAU DELA HORIE Robert A. HAMM Peter N.KELLOGG Patrick VINK Biogen Announces Several New Appointments in its International Commercial Organization Robert A. Hamm has been named senior VP of the international commercial organiza tion, replacing Mark Leuchtenberger, who announced his intention to resign at the end of 2001. He joined Biogen in 1994 and has played a critical role in building the company’s international commercial structure and operat ing capability. Most recently, he was VP of sales and marketing, where he was responsible for reinvigorating the growth rate of Avonex, the company’s multiple sclerosis product. GuyCharles Fanneau dela Horie has been named VP of strategic commercial operations, international. Mr. Fanneau dela Horie joined Biogen in 1995 as country manager responsi ble for launching Avonex in France. Most recently, he has been responsible for several assignments in the U.S., including the posi tions of national sales director and commercial program executive for Avonex. Patrick Vink has been appointed VP of sales responsible for international affiliates. Mr. Vink joined Biogen in 2000 as country manager, Germany. “I am delighted that this team is assuming leadership of our European organization,” says James C. Mullen, president and CEO. “Bob and GuyCharles were responsible for the reposi tioning of our U.S. commercial operations, resulting in reinvigoration of the Avonex mar ket during the past year. They have both worked together before in the European busi ness. Our performance in Europe has been strengthened over the past year, and I am confi dent that this team will accelerate that trend.” In a separate move, Biogen has named Frank A. Burke, Jr. to the role of executive VP of human resources. Mr. Burke joined Cam bridge, Mass.based Biogen in 1986 after a 12year career with Allied Signal Corp. He has supervised the global human resources func tion throughout Biogen’s growth from a bou tique research organization into a multiprod uct global biopharmaceutical company. Specialty POOL Kathleen HAMILTON Bradley Pharmaceuticals Adds Senior Director of International Marketing and Sales Kathleen Hamilton, who has more than 25 years experience in the pharmaceutical indus try, joins Bradley Pharmaceuticals Inc., a spe cialty pharmaceutical company, as senior director of international marketing and sales. Most recently, Ms. Hamilton held the position of director of sales and marketing operations with FiberTec Inc., a manufactur er of singleuse healthcare products. She has extensive knowledge of the pharmaceutical market and the regulations governing the industry. “Her experience in national and interna tional market activity and product perfor mance will be invaluable as Bradley continues to implement an aggressive growth strategy in the U.S. and abroad. We are confident that her expertise will help the company achieve the ambitious goals management has set for 2001, and beyond,” says Daniel Glassman, president and CEO of Fairfield, N.J.based Bradley. TALENT pool G.Thomas HEATH Carol A. GONZALEZ, Ph.D . NPS Pharmaceuticals Expands Commercial Organization With Executive Appointments The appointment of G. Thomas Heath as senior VP of sales and marketing at NPS Phar maceuticals Inc. comes as the specialty pharma company moves to expand its commercial orga nization and its plans to participate in the mar keting of several of its nearterm products. For 20 years, Mr. Heath served in various marketing and sales posi tions at Pfizer Inc., where he managed the prelaunch planning and successful introductions of a number of new pharmaceutical products, including Nor vasc, the world’s biggest selling medicine for hyper tension and angina. He joins NPS from Echelon Research Laboratories, a company he cofound ed in 1997, where he served as president and where he will continue to serve as a director. In addition to Mr. Heath, NPS has appoint ed Carol A. Gonzalez, Ph.D., as director of business development to expand the company’s business development and licensing efforts. She has many years experience in biotech and healthcare product marketing, licensing, and business development, and previously held positions at McCulley/Cuppan, Becton Dick inson, and Kendall Healthcare Products. “Tom and Carol bring many years of phar maceutical sales, marketing, and business development experience to our company at a time when our product pipeline is growing and maturing rapidly,” says Hunter Jackson, Ph.D., chairman, CEO, and president of NPS. “With these appointments, we are adding considerable talent to our management team and laying the groundwork for the commer cial success of our products.” NPS, Salt Lake City, is developing propri etary potential therapies for the treatment of osteoporosis and gastrointestinal disorder, and has options to jointly promote certain com pounds in development with GlaxoSmith Kline for the treatment of osteoporosis, and with AstraZeneca for the treatment of central nervous system disorders. Robert M.JANOSKY Cellegy Pharmaceuticals Appoints Director of Marketing Cellegy Pharmaceuticals Inc. has appoint ed Robert M. Janosky as director of market ing, responsible for directing the prelaunch preparation, launch, and marketing of Celle gy’s pharmaceutical products in the U.S. Mr. Janosky also is responsible for interact ing with pharmaceutical companies interested in jointly promoting or licensing Tostrex, a testosterone gel, in the U.S. Mr. Janosky joins Cellegy, South San Francisco, Calif., from Alza Corp. where he developed launch plans and marketing programs for Ditropan XL, a treat ment for overactive bladders. In this capacity he developed and implemented innovative marketing programs directed at physicians, pharmacists, and consumers, achieving annual sales of $200 million a year in the U.S. He was responsible for coordinating promotional activities with Alza’s joint promotion partners for Ditropan XL — Johnson & Johnson and UCB Pharma — as well as with Innovex, with whom Alza had developed a salesforce target ed to primarycare physicians. His earlier experience in the pharmaceutical industry includes marketing planning, marketing research, and sales at American Home Prod ucts Corp. and Fisons Pharmaceuticals. Mr. Janosky holds an undergraduate degree in biochemistry and an MBA in marketing and finance. Robert J. LOLLINI Iomed Announces Senior Management Change Robert J. Lollini has been named chief operating officer of Iomed Inc., a specialty pharmaceutical company. Formerly executive VP and chief financial officer, Mr. Lollini has assumed management of the company’s day today operations. He also continues to serve as CFO. Mr. Lollini’s new duties replace those of James R. Weersing, who resigned as presi dent and CEO. In addition, Mr. Weersing resigned his director seat on the company’s board of directors. Peter J. Wardle, chairman, says a search for a president and CEO will commence at a later date, with Mr. Lollini as a candidate for the position. Mr. Lollini manages the Salt Lake Citybased company’s corporate, financial, and strategic direction, including strengthening its relationships with key business partners, customers, and employees. Ross MACDONALD, Ph.D. Connetics Names Dermatology Expert as VP of Business Development Connetics Corp., which is focused on devel oping therapeutics for the dermatology mar ket, has appointed Ross Macdonald, Ph.D., to the newly created position of VP of business development. Dr. Macdonald is responsible for all aspects of the company’s global business development efforts, and reports to John L. Higgins, chief financial officer and executive VP of finance and administration. Before joining Palo Alto, Calif.based Con netics, Dr. Macdonald was VP of R&D at F.H. Faulding & Co. Ltd., an Australian pharma ceutical and healthcare company. He also served as managing director of Soltec Research, where he led that company’s empha sis on dermatology and established its many commercial relationships with dermatology companies worldwide. “We are extremely pleased that Dr. Mac donald has joined the Connetics team,” Mr. Higgins says. “Ross has an intimate knowledge of our topical drugdelivery technologies and its broad applications in dermatology, having recently served as the managing director of Soltec Research. In addition, Ross has extensive knowledge of the dermatology field and the pharmaceutical industry, both in the U.S. and throughout the world. He joins us at an impor tant and exciting time as we look to expand our dermatology business beyond our current prod uct development and commercial programs.” Dr. Macdonald has a Ph.D. in biochemistry from Monash University, Melbourne, Aus tralia, and a postgraduate diploma from the Business School of Swinburne University in Australia. Joseph PAPA Industry Veteran to LeadWatson’s Commercial Operations Joseph Papa has joined Watson Pharma ceuticals Inc. as chief operating officer, bring ing to the specialty company a depth of indus try experience in all facets of the sales and marketing process. “It is with great pleasure that I welcome Joe into the Watson organization,” says Allen Chao, Ph.D., chairman and CEO. “Joe’s lead ership and depth of marketing and operations experience will prove to be a tremendous asset to our organization as we progress with our growing branded franchise.” Mr. Papa, 46, is responsible for the com mercial operations side of Watson’s business, including sales and marketing, sales opera tions and distribution as well as overall manu facturing operations. He reports directly to Dr. Chao. Before joining Corona, Calif.based Wat son, Mr. Papa was president and chief operat ing officer for DuPont Pharmaceuticals. He also has held senior positions at Searle Phar maceuticals, where he orchestrated the suc cessful U.S. launch of the COX2 inhibitor 81 PharmaVOICE J a n u a r y / F e b r u a r y 2 0 02 TALENT pool Celebrex, and also at Novartis, Ciba Geigy, and Geneva Pharmaceuticals. A registered pharmacist, Mr. Papa received his undergraduate degree in pharmacy from the University of Connecticut. He received his masters of management degree in marketing and finance from the J.L. Kellogg Graduate School of Management at Northwestern Uni versity. Marinko VEKOVIC ICN Promotes Sales Executive to Worldwide Division Marinko Vekovic has been named senior VP of worldwide corporate sales and market ing at ICN Pharmaceuticals Inc., which mar kets and distributes more than 800 prescrip tion and nonprescription pharmaceuticals in more than 100 countries. Since joining Costa Mesa, Calif.based ICN, in March, 1999, Mr. Vekovic has served as VP of sales and marketing in Eastern Europe, Central Europe, and Western Europe. He directly reports to Milan Panic, chairman and CEO. Previously, Mr. Vekovic was president of Pharma Consulting Co., which assists mid size pharmaceutical companies in Denmark, Greece, Italy, and the U.K. explore emerging market development. After receiving his bachelor of science degree in economics from London University, England, Mr. Vekovic earned an MBA degree from the International Management Develop ment Institute based in Lausanne, Switzerland. Genomics POOL Paul A. FRIEDMAN,M.D. Robert STEIN,M.D., Ph.D Incyte Taps Industry Leaders for Senior Ranks Incyte Genomics Inc., a genomics informa tion company, has appointed two industry leaders to its senior ranks — Paul A. Fried man, M.D., as CEO, and Robert Stein, M.D., Ph.D., as president and chief scientific officer. Both Dr. Friedman and Dr. Stein join Incyte from DuPont Pharmaceuticals Research Laboratories. Dr. Friedman was pres ident of the company, while Dr. Stein was executive VP of research and preclinical devel opment. Roy A. Whitfield, joint founder and previ ous CEO of Incyte, has been elected chairman, succeeding joint founder Randy Scott, Ph.D. “Dr. Friedman and Dr. Stein are proven leaders who together created an impressive therapeutic pipeline at DuPont while build ing substantial value for DuPont’s sharehold ers,” Mr. Whitfield says. “Incyte’s intellectual property portfolio — consisting of the indus try’s largest compilation of antibody, protein, and gene patents — provides them significant pharmaceutical opportunities to apply their leadership skills to expand the database and intellectual property licensing business and develop new medical therapeutics.” Dr. Friedman held the position of president at DuPont Pharmaceuticals from 1994 until the acquisition of the division by Bristol Myers Squibb for $7.8 billion in September 2001. During his tenure, the number of high quality drug candidate compounds nominated for clinical development tripled, reaching 10 in the 2000. Notable among these is Sustiva for the treatment of HIV. Dr. Friedman is a diplomat of the American Board of Internal Medicine and is a member of the American Society of Pharmacology and Exper imental Therapeutics, the American Society of Clin ical Investigation, and the American Society of Biological Chemists. Dr. Stein joined Dr. Friedman at what was then DuPont Merck Pharmaceuticals as Exec utive VP of research and preclinical develop ment in 1996. Dr. Stein and Dr. Friedman had previously worked together at Merck & Co. from 1982 until 1990, at which time Dr. Stein was senior director and head of the department of pharmacology. Dr. Stein holds a B.S. in biology and chemistry from Indiana University and a M.D. and Ph.D. in physiol ogy and pharmacology from Duke University. 82 J a n u a r y / F e b r u a r y 20 0 2 PharmaVOICE Device/Diagnostics POOL Peter H.GLICK Cohesive Technologies Appoints President and CEO With experience as head of a midsize com pany, Peter H. Glick has been named president and CEO of Cohesive Technologies Inc., a developer and manufacturer of novel liquid chromatography systems and chemistries for the drugdiscovery marketplace. From 1998 until his appointment at Cohe sive Technologies, Mr. Glick was president of Primedica Corp., a 650employee contract research organization that provides safety and efficacy testing, product development, and production services to more than 300 pharma ceutical, biotechnology, and medical device companies. Primedica operated as a stand alone subsidiary of Genzyme Transgenics Corp. Mr. Glick holds a master’s degree in man agement from The Sloan School of Manage ment at Massachusetts Institute of Technolo gy, and a bachelor’s degree in economics from The Wharton School. Lucia Luce QUINN Quest Diagnostics Creates New Position of Senior VP, Advanced Diagnostics Quest Diagnostics Inc., a provider of diag nostic testing, information, and services, has named Lucia Luce Quinn as senior VP of advanced diagnostics. In this newly created position, Ms. Quinn is responsible for leading Quest Diagnostics’ efforts in aligning strategy, busi ness development, and innovation. In her new role, Ms. Quinn draws upon her experience in marketing and research and development to accelerate the rate at which Teterboro, N.J.based Quest Diagnostics brings new products and services to market. Ms. Quinn joined Quest Diagnostics in April, 2001, as VP of developing businesses. Previously, she served as VP of corporate strategic marketing at Honeywell Internation al. She has more than 25 years experience in general management, marketing, operations, business planning, and strategy development with global technology companies, including Allied Signal, Digital Equipment, and West inghouse. Drug Delivery POOL Edward M.CHAIT,Ph.D. PharmaCore Names President and CEO PharmaCore Inc., a drug discovery compa ny, has appointed Edward M. Chait, Ph.D., to the position of president and CEO. Dr. Chait joins High Point, N.C.based TALENT pool 83 PharmaVOICE J a n u a r y / F e b r u a r y 2 0 02 PharmaCore after 10 years at Intergen Co., a manufacturer of biochemicals for diagnostics and biopharmaceuticals and research products for high throughput screening, drug discov ery, and genomics. At Intergen, Dr. Chait was senior VP of business development and tech nology, and directed Intergen’s R&D, strategic planning and acquisitions. Before Intergen, Dr. Chait worked 23 years at DuPont in vari ous positions in R&D, sales, marketing, and corporate development. Dr. Chait holds an AB in chemistry from Cornell University and a Ph.D. in analytical chemistry from Purdue University. He has served on the visiting committee of NIST, as chairman of the BIO business development committee, and as a member of the executive committee of the U.S. Israel Technology Com mission of the U.S. Department of Commerce. Michael MCCLURG Epimmune Appoints VP of Business Development A veteran of the biotech and pharmaceuti cal industries, Michael R. McClurg assumes the position of VP of business development at Epimmune Inc. Mr. McClurg is responsible for licensing arrangements, developing corpo rate alliances, and business development strategies for Epimmune’s proprietary Epitope Identification System, ImmunoStealth, Padre, and vaccine technologies. Before joining Epimmune, Mr. McClurg was director of business development at Prometheus Laboratories. During his career, he has held various positions at Isis Pharma ceuticals, Ligand Pharmaceuticals, and Immunetech Pharmaceuticals. “Mike’s diverse background, including both industry experi ence and the range of positions he has held is a significant advantage for Epimmune,” says Emile Loria, M.D., president and CEO of San Diegobased Epimmune. “In addition to the clinical trial plans for our HIV and lung can cer vaccine candidates, there are opportunities for us to develop partnerships to enhance the value of our core technologies in epitope iden tification.” Epimmune uses gene maps of cancerassoci ated proteins and infectious agents to design vaccines that induce cellular immunity. The technology is based on deciphering the genetic code which regulates Tcell activation and in identifying antigen fragments known as epi topes which can activate targeted Tcell respons es to tumors, viruses, bacteria, and parasites. Dr. Cossum received his bachelors and masters degrees and a doctorate at the Univer sity of Tasmania, in Australia. Mark FURTH,Ph.D. Incara Selects Leader for Tissue Research Seeking to expand applications for its tis sue protection, repair, and regeneration tech nologies Incara Pharmaceuticals Corp. has brought in molecular biologist Mark E. Furth as senior VP of research. Dr. Furth is oversee ing Incara’s work on therapies to treat liver failure, including use of adult liver stem cells for gene therapy and genomics and the use of Incara’s catalytic antioxidants in cell therapy and metabolic diseases. Dr. Furth has 15 years of executive experi ence in the biopharmaceutical industry. He was chief scientific officer at PPD Discovery, a com pany focused on drug discovery platforms, including functional genomics and combinato rial chemistry from 1997 to 2000, before join ing PPGx, a pharmacogenomics company. Dr. Furth has a B.A. in biochemical sciences from Harvard University and a Ph.D. in molec ular biology from the University of Wisconsin Madison. He carried out postdoctoral research at the Medical Research Council Laboratory of Molecular Biology, Cambridge, U.K., and the National Cancer Institute. Howard P. RICHMAN, D.P.M. Biopure Appoints VP of Regulatory Affairs and Compliance Howard P. Richman, D.P.M., has joined Biopure Corp. as VP of regulatory affairs and compliance, while Edward E. Jacobs, Jr., M.D., has retired from his fulltime position as senior VP of medical affairs, and returned to his previous role as a consul tant to the company. Dr. Richman, 49, brings to Biopure more than 20 years of regulatory experience in qual ity assurance and chemistry, manufacturing and controls, which he gained in the corporate sector and as a consultant for the U.S. Food and Drug Administration. He has directed numerous regulatory submissions, including new drug applications and biologic license applications in the U.S. and marketing autho rization applications in Europe. Dr. Richman’s responsibilities at Biopure include implementing a global regulatory strategy for the company’s pharmaceutical products, serving as the primary contact with the FDA and other regulatory authorities, building and overseeing the regulatory and compliance staff and activities, and directing the company’s contracted regulatory consult ing groups. He reports to Biopure President Paul A. Looney. He joins Biopure from MacroChem Corp., where he was senior director of regulatory affairs, quality assurance, and chemistry, man ufacturing, and controls. Dr. Richman is an International Organization of Standardization 9000 and 9001 certified auditor and is a mem ber of the Regulatory Affairs Professional Soci ety and the American Society for Quality. He received a doctorate of podiatric medicine from New York College of Podiatric Medicine and a B.S. degree in chemistry and biology from St. John’s University in New York City. Dr. Jacobs, 61, began working with Biop Emerging POOL Paul COSSUM,Ph.D. NewBiotics Adds Executive VP of Drug Development NewBiotics Inc., a developer of break through drugs to treat cancer and infectious dis ease, has appointed Paul Cossum, Ph.D., as execu tive VP of drug develop ment. Dr. Cossum is responsible for directing the advancement of drug candidates from the discovery phase through preclinical and clini cal development toward marketable pharma ceutical products. “With his expertise and management experience, the addition of Paul to our team is timely as we advance our lead drug candidate, NB1011, into clinical trials for patients with drugresistant colon cancer,” says Thomas Mizelle, CEO of San Diegobased New Biotics. “We’re excited to have his energy and drive as we continue to develop our unique ECTA technology platform to address cancer and infectious disease,” he says. Dr. Cossum, 49, brings to NewBiotics more than 15 years of industry experience in drug development. Before joining NewBi otics, he served as VP of preclinical research and development and business development at Aronex Pharmaceuticals Inc. Dr. Cossum’s responsibilities included overseeing pharma cology, pharmacokinetics, and toxicology studies and analytical development for anti cancer and antiinfective drug candidates. TALENT pool 84 J a n u a r y / F e b r u a r y 20 0 2 PharmaVOICE ure as an advisor in 1984, joined the company as medical director in 1991, and became a senior VP in 1997. During that time, he con tributed to patents and publications, helped design preclinical and clinical studies, and played an important role in understanding how hemoglobin in plasma carries oxygen throughout the body. Service POOL Charles BEARDSLEY CBTechnologies MoreThan Doubles Sales Team CBTechnologies Inc., a provider of clinical elec tronic datacapture soft ware and related services to the lifesciences indus try, has more than doubled its professional sales team amid growing demand for its MetaTrial EDC solu tions from pharmaceutical and biotechnology companies, medical device manufacturers, and contract research organizations. To enhance its level of service and proac tive partnering with clients, Exton, Pa.based CB Technologies also is introducing a team based solutions sales approach. CB Technolo gy’s sales teams now include crossfunctional skills represented by four leaders: a business team leader, a client services manager, a sales executive, and a sales engineer. Leading the effort is Charles “Rusty” Beardsley, CB Technology’s senior VP of sales and marketing. Mr. Beardsley has successfully optimized sales efforts for RhonePoulenc Rorer — now Aventis — where he designed and implemented the team concept across 150 teams and more than 1,000 sales professionals. CB’s newly formed business teams are led by: Ken Billard, Zach Marks, Robert “Bo” Wilk erson, Chris Mattheus, Beverly Hudson, and Matt Huberty. “These are highly skilled and serviceori ented individuals,” Mr. Beardsley says. “They possess the leadership skills that are critical to steering CB’s course into an exciting future — a future that will challenge and bring out the best in our people.” Bob BROWN Fast Track Names Experienced Industry Executive as President, Chief Operating Officer With extensive experience in pharmaceuti cal and healthcare data management, informa tion technology and finance, Bob Brown assumes the posts of president and chief oper ating officer at Fast Track Systems Inc. Before joining Fast Track, San Mateo, Calif., Mr. Brown was CEO and president of Solucient LLC and its predecessor company HCIASachs, an international organization with the largest repository of healthcare intelligence and bench mark information in the industry. “Bob’s executive experience at NDC and Solucient is a perfect match for Fast Track’s datadriven business model,” says Jim McCord, chairman and CEO of Fast Track, a medical informatics technology company that provides information, design, and execution tools for the clinical development community. “His expertise and deep knowledge of the pharmaceutical data market will help us to enhance our position as one of the industry’s leading suppliers of clinicaltrials data and clinicalinformatics tools. His extensive oper ating background will also help us to manage our rapid growth.” Joseph L. HERRING Covance Elects President and Chief Operating Officer Covance Inc. has elect ed Joseph L. Herring as president and chief oper ating officer, promoting him from the position of senior VP and president of early development ser vices. Mr. Herring has operating responsibility for Covance’s business units worldwide and will report to Chairman and CEO Chris Kue bler. “This move reflects Covance’s commitment to building a team of superior operational leaders with the talent and experience to deliv er outstanding service levels and to create more strategic relationships with all of our customers,” Mr. Kuebler says. “Joe already has helped accomplish this in Covance’s early development business, and now he will have the opportunity to apply his skills across our full range of services.” Chief operating officer is a new position for Princeton, N.J.based Covance, a drugdevel opment service company. Mr. Herring, 46, joined Covance in 1996 as corporate VP and general manager of laboratories North Ameri ca, the company’s preclinical testing group, then moved to early development services in 1999. Under Mr. Herring’s leadership, early development services has grown significantly and today represents one of Covance’s most profitable and most strategic businesses. He was responsible for extending key early devel opment capabilities into new markets, and implemented new systems and technologies to enhance the quality and timeliness of toxicol ogy data for Convance’s customers. Mr. Herring holds a bachelor of science degree from Louisiana State University. Susan D.MATHIAS Ovation Research Group Names VP of PatientReported Outcomes Ovation Research Group, a global health economics and outcomes research and consult ing company, has appointed Susan D. Mathias as VP of patientreported outcomes. Ms. Mathias is responsible for business development and for project design and senior scientific oversight for projects related to patientreported outcomes. Previously, Ms. Mathias served as VP of the Health Outcomes Group at the Lewin Group, a subsidiary of Quintiles Corp., where she was responsible for the development and design of patientreport ed outcomes research. “Susan joining Ovation is a response to our clients’ evolving need to explore humanistic endpoints — quality of life, treatment satisfac tion — in a more structured, scientific man ner,” says Jeff Trotter, president of Highland Park, Ill.based Ovation. “Increasingly, the value of new drugs, devices, and treatment reg imens is being assessed from the patient’s per spective. This, in turn, reflects increased levels of patient empowerment and influence on medical decisionmaking. Susan’s extensive experience in this field is relatively unique, while being quite complimentary to Ovation’s core competencies in outcomes research, health economics, and disease/product registries.” Suppliers POOL Jayne CHAPLICK Jackie DILLON Margaret NOON Doctors+Designers Expands Company Roster With Three Appointments Doctors+Designers, a health education company for the pharmaceutical industry, has added a new account manager to its salesforce, Jayne Chaplick. Ms. Chaplick held positions in pharma ceutical sales and healthcare ad agency account management, most recently as senior account executive with FCB HealthCare. TALENT pool 85 PharmaVOICE J a n u a r y / F e b r u a r y 2 0 02 “Jayne is a great addition to our account team by virtue of her diverse experiences in the pharmaceutical industry and her innate under standing of our customers needs,” says Diane Teasdale, VP of client services at Westfield, N.J.based Doctors+Designers. “She is respon sible for presenting and selling our distinctive Strategic Health Education Programs.” Ms. Chaplick is a graduate of Slippery Rock University. In addition, Margaret Noon has been named to the newly created position of creative director and Jackie Dillon to the newly created position of art director. Ms. Noon is responsi ble for developing and leading the creative team of writers, designers, illustrators, and photographers on inquiries and assigned pro grams. Ms. Dillon has joined the design team to create and implement the company’s educa tional concepts. Ms. Noon, who has an extensive creative background in both Rx and OTC medications, was most recently senior VP, creative director, at Lowe McAdams Healthcare in New York, where she started the Madison Ave. office and supervised the creative department. Ms. Noon also served as senior VP, associate creative direc tor at Sudler & Hennessey Inc., where she was responsible for Amgen’s Neupogen, Hoffmann La Roche’s Rocephin, AstraZeneca’s Diprivan and Zoladex, amongst other major pharmaceu tical brands. She holds a BFA in communica tion design from the Pratt Institute. Ms. Dillon brings a strong background in concept and design work, having most recent ly held the position of senior art director at Sandler Communications, a New York health care advertising agency. While at Sandler Communications, she worked on such health care accounts such as Medeva Pharmaceuti cals, Aventis Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals. Ms. Dillon also has served as art assistant at Mark Weinberg Design and junior art director at Todd Lerner Advertising with a focus on consumer accounts such as Tommy Boy Records, Ad Club of NY, and the Smith sonian. She holds a BFA in Communication Design from the Pratt Institute. “We are very fortunate to expand our art and design department team with key creative experts of Margaret’s and Jackie’s caliber,” says Roy Broadfoot, president and CEO of Doc tors+Designers. “Their indepth experience in creative management and pharmaceutical advertising will enhance our awardwinning and creative healtheducation work.” Jeff SMITH Pharmaceutical Direct Appoints Business Development Manager Pharmaceutical Direct Inc., a direct mar keting company based in Dover, N.J., has appoint ed Jeff Smith as business development manager. Mr. Smith has more than 15 years of experi ence providing direct marketing services to the pharmaceutical industry, including database building programs, direct mail strategies, coupon programs, and DTC/DTP programs. He comes to Pharma ceutical Direct from PPS Medical Marketing Group. Angela WALLACE Search Masters Opens San Diego Office, Names Executive to Lead Western Operations Search Masters International, a unit of Kelly Scientific Resources, a leader in scientif ic staffing, has opened an office in San Diego, and named executive recruiter Angela Wallace to head the office. She has been in the recruiting industry for more than three years, and has specialized in scientific recruitment for the past two years with Kelly Scientific Resources.Ms. Wallace holds a bachelor of science degree in chemistry from Louisiana Tech University. Search Masters International serves numer ous disciplines in the biotech and pharmaceu tical fields. Its San Diego office serves pharma ceutical and biotech companies in the Western states with particular emphasis on Seattle, San Francisco, San Diego, and Denver. Media POOL David BURDA Barbara KIRCHHEIMER Modern Healthcare Promotes Two Journalists to Positions of Editor, News Editor Awardwinning journalist David Burda has been promoted to the position of editor of Modern Healthcare, while Barbara Kirchheimer fills the position of news editor. Mr. Burda, 41, has been Modern Healthcare’s news editor since December 1996. He joined the weekly news magazine in 1987 as a reporter, covering legal affairs, labor and quali ty of care. In 1993, Mr. Burda won a Jesse H. Neal Award by the American Business Press for best magazine story of the year for his June 15, 1992, Modern Healthcare article on hospital charity care. Mr. Burda replaces longtime edi tor, Clark Bell, who was recently named pub lisher of sister publication, Modern Physician. Mr. Burda holds a MA in journalism from Indiana University and a BA in English from Elmhurst College. Ms. Kirchheimer, 31, who takes on the role vacated by Mr. Burda has been a reporter covering investorowned hospitals for Modern Healthcare since 1999. Before joining Modern Healthcare, Chicago, Ms. Kirchheimer was a business reporter at the Kalamazoo Gazette, a daily newspaper in Michigan, and a senior Capitol Hill reporter for the weekly tax policy magazine, Tax Notes. She holds a master of science degree in jour nalism from Columbia University’s School of Journalism, New York, N.Y., and a BA in political science from Williams College, Williamstown, Mass. Michael D. MAVES,M.D. AMA Selects Medical and Association Management Expert to Head Organization Michael D. Maves, M.D., takes over as execu tive VP and CEO of the American Medical Asso ciation, the nation’s oldest and largest physician’s group. Dr. Maves, 53, brings extensive medical and association management experience to his new AMA position. He served as executive VP of the American Academy of Otolaryngology — Head and Neck Surgery Inc. from 1994 to 1999. Most recently, he headed the Consumer Healthcare Products Association in Washing ton, D.C. “Dr. Maves is a proven leader who has dis tinguished himself across many fronts — academia, organized medicine, and association management,” says Timothy T. Flaherty, M.D., chairman of the AMA Board of Trustees. “The AMA is excited about the leadership and vision he will bring to our association.” An active participant in organized medicine throughout his professional career, Dr. Maves has served as a specialty society rep resentative and alternate delegate to the AMA House of Delegates as well as a governor of the American College of Surgeons. He has served as a member of the board of the St. Louis Metropolitan Medical Society, a councillor of the St. Louis Surgical Society, and a delegate to the Missouri State Medical Association. Dr. Maves was a member of the initial AMA ResourceBased Relative Value Scale Update Committee, and has testified before Congress, the Centers for Medicare & Medicaid Services TALENT pool 86 J a n u a r y / F e b r u a r y 20 0 2 PharmaVOICE and the Food and Drug Administration. In addition, he is a consultant to the clinical cen ter at the National Institutes of Health in Bethesda, Maryland. He currently cochairs the medical/surgical panel of the CMS Medi care Coverage Advisory Committee and serves on its executive committee. A clinically trained and boardcertified oto laryngologist, Dr. Maves has distinguished himself in academic circles as well. He has served as professor and chairman for the Department of Otolaryngology — Head and Neck Surgery at Saint Louis University College of Medicine. He also has held faculty appoint ments at the University of Iowa Hospitals and Clinics, and at Indiana University School of Medicine. Presently, he is adjunct professor at the Saint Louis University School of Medicine and at the Georgetown University Medical Center, where he still practices part time. Dr. Maves is the author of about 100 peer reviewed medical journal articles and book chapters, and has lectured extensively on such topics as headandneck surgery, medical prac tice and medical economics. He received his undergraduate degree from the University of Toledo and his medical degree from The Ohio State University. He received his MBA from the University of Iowa College of Business Administration. Agency POOL Mark ALVINO Feinstein Kean Healthcare Announces Promotion Feinstein Kean Healthcare, an Ogilvy PR Worldwide company, has promoted Mark Alvino to senior VP of corporate communica tions from VP of the division. In this capacity, he continues to provide senior strategic counsel to clients, grow exist ing business, and spend a significant portion of his time on new business efforts. Mr. Alvino joined Cambridge, Mass.based FKH in October 2000, and has been responsi ble for managing both investor and corporate communications programs for many private and public companies. “Mark’s insight and expertise in investor relations has been critical to successful pro grams for many of our clients,” says Pat Jones, managing director. “In his new role, we can expand his senior counseling across our client base and create new programs for reaching the investor community.” Before joining FKH, Mr. Alvino served as VP of investor relations and managed the New York office of Allen & Caron, Inc., an investor relations agency. Ben FRYE Zarie LOROW Michelle YOUNG AdTech Communications Adds to Staff AdTech Communications, Hollywood, Fla., which is undergoing significant expan sion with projections for continued growth into 2002, has named Ben Frye to the client servicing team. As an account executive, Ben applies an extensive knowledge base of bio chemistry, microbiology, anatomy, physiology, nutrition and alternative therapies with expe rience in medical and healthrelated sales, sales training, and marketing. Mr. Frye’s sales and marketing experience covers a broad range of products, professional, and paramedical audiences and pointsoftrade including primarycare physicians, dermatolo gists, plastic/cosmetic surgeons, women’s health clinics, rehabilitation units, pharma cists, aestheticians, consumers/patients, and healthrelated wholesalers and retailers. His marketing communications experience covers these same audiences and includes the success ful implementation of personal selling, trade shows/special events, traditional broadcast, interactive electronic, and outdoor media. In related agency news, Michelle Young koins AdTech as traffic manager. Ms. Young manages the logistics and scheduling of jobs within the agency and shepherds each project successfully through a system and process she designed in conjunction with the agency’s management and IT team. “The system and process, though internal to the operations of the agency, are truly clientcentered,” says Dan Palmer, AdTech Management Partner. “They coordinate the account servicing, creative, proofing/editing, production, media planning, finance, and administrative resources of the agency to effi ciently achieve the balance of timing, quality, promotional impact, and cost that have become an AdTech hallmark on every pro gram the agency undertakes for clients.” In addition, Zarie Lorow joins the agency as production manager. Ms. Lorow brings a mar keting, sales promotion, printing, paper, and graphic reproductions background to the posi tion of production manager. She has experience as an account executive, marketing manager, sales promotion manager, and production manager. Ken LIATSOS Lehman Millet Taps Agency Veteran as Director of Client Services Agency veteran Ken Liatsos has joined LehmanMillet Inc. in the new position of VP and director of client services, focusing on ensuring continuity of client service in the midst of agency growth. Mr. Liatsos brings more than 15 years at top New England agen cies to Lehman Millet. He has managed accounts for many large national and multina tional corporations, including American Express, AT&T, Humana, Express Scripts, Harvard Pilgrim Healthcare, Mobil Oil Corp., and British Airways. In addition, as VP and practice leader of Hill Holiday’s Integrated Healthcare Marketing Group, Mr. Liatsos gained broad strategic insight into healthcare industry issues. “Ken Liatsos is a seasoned strategist and account professional,” says Bruce Lehman, president and CEO of the Bostonbased agen cy. “As we continue our rapid growth, we want to ensure that our focus remains on delivering clients shrewd strategy, outstand ing creative, and exceptional service. Ken will make sure we do.” Health!Quest Global Communication Partners, the healthcare marketing services network, acquired Lehman Millet as its flag ship company in the device and diagnostics sector. Please send your personnel announcements to feedback@pharmalinx.com. Employee recruitment and selection Top pha rmaceu t i ca l compan es believe that yearround recruitment is a valueadded process that is critical to the company’s future growth. Among the key components of man aging recruitment and selection as an ongoing core process, according to Best Practices LLC ,a re designing an automat ed front end to screen candidates, accu rate corporate forecasting of recruitment needs, tracking key recruitment mea sures, and implementing strategies to deal with advancements and trends in the recruitment process. INDUSTRY SNAPSHOT

Posted in:

Post a Comment

You must be logged in to post a Comment.